This company listing is no longer active
Myovant Sciences Future Growth
Future criteria checks 5/6
Key information
59.0%
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 31.7% |
Revenue growth rate | 27.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 10 Mar 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2025 | 618 | -74 | N/A | N/A | 2 |
3/31/2024 | 555 | -76 | N/A | N/A | 3 |
3/31/2023 | 418 | -153 | N/A | N/A | 2 |
12/31/2022 | 379 | -184 | -271 | -270 | N/A |
9/30/2022 | 333 | -190 | -260 | -259 | N/A |
6/30/2022 | 306 | -166 | -232 | -231 | N/A |
3/31/2022 | 231 | -206 | -270 | -269 | N/A |
12/31/2021 | 198 | -228 | -263 | -261 | N/A |
9/30/2021 | 145 | -238 | 403 | 405 | N/A |
6/30/2021 | 67 | -284 | 318 | 319 | N/A |
3/31/2021 | 59 | -255 | 369 | 371 | N/A |
12/31/2020 | 35 | -239 | 443 | 444 | N/A |
9/30/2020 | 33 | -250 | -198 | -197 | N/A |
6/30/2020 | 33 | -254 | -217 | -216 | N/A |
3/31/2020 | N/A | -289 | -222 | -221 | N/A |
12/31/2019 | N/A | -299 | -256 | -255 | N/A |
9/30/2019 | N/A | -284 | -252 | -250 | N/A |
6/30/2019 | N/A | -279 | -247 | -246 | N/A |
3/31/2019 | N/A | -274 | -225 | -224 | N/A |
12/31/2018 | N/A | -247 | -207 | -206 | N/A |
9/30/2018 | N/A | -218 | -176 | -175 | N/A |
6/30/2018 | N/A | -182 | -136 | -135 | N/A |
3/31/2018 | N/A | -143 | -118 | -117 | N/A |
12/31/2017 | N/A | -117 | -94 | -93 | N/A |
9/30/2017 | N/A | -83 | -70 | -69 | N/A |
6/30/2017 | N/A | -88 | -46 | -45 | N/A |
3/31/2017 | N/A | -83 | -19 | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 71M is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: 71M is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 71M is expected to become profitable in the next 3 years.
Revenue vs Market: 71M's revenue (27.6% per year) is forecast to grow faster than the German market (3.4% per year).
High Growth Revenue: 71M's revenue (27.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 71M's Return on Equity is forecast to be high in 3 years time